A P/B of 1.29x paired with a trailing P/E near 10x implies the market expects sustained returns close to a moderate cost of equity rather than a premium for franchise quality. Compared with Travelers at 2.73x P/B and 26.2% ROE, RGA's valuation discount appears driven by its lower reported returns and the lumpiness of its earnings base. Investors should monitor whether ROE can move toward double digits, since that gap, rather than headline growth, appears to be what would close the multiple.

The move in the loss ratio from roughly 87% in 2025 to the 67% to 78% range in 2026 accounts for most of the improvement, which suggests favorable claims experience rather than structural expense gains. Expense ratios swing widely between 6% and 24%, which may indicate timing effects in deferred acquisition cost amortization and transaction-driven expenses. Warrants further investigation into how much of the 2026 improvement reflects sustainable mortality experience versus reserve or assumption timing.

With investment income fields unpopulated in the supplied data, the contribution of float income to ROE cannot be separated from underwriting results. The gap between a 9.5% underwriting margin and a 3.6% ROE implies that leverage, capital base size, and non-underwriting items absorb a significant portion of economic profit. This suggests the company's return profile depends heavily on investment yield on its large asset base, which warrants closer review once that data is available.

Total liabilities rising to roughly 93% of assets indicates that the balance sheet is becoming more levered even as reported interest coverage improves to 7.5x. Premium growth relative to surplus cannot be fully verified from the supplied data, but the expanding asset base against modest equity growth appears to tighten the capital cushion. Investors should monitor whether statutory capital keeps pace with the growth in reserves and treaty volume.

The valuation discount relative to peers appears justified by weaker reported returns, even though RGA's low PEG may signal that expected earnings growth is not fully reflected in the price. Peers such as RenaissanceRe and Greenlight trade at lower P/B multiples with comparable or lower ROE, so RGA is not the cheapest name in the group on book value. The comparison suggests the stock's relative attractiveness depends on whether management can convert the reported growth into sustained returns above the peer median.